SCHEMBL12640776

SCHEMBL12640776

CC(C)/C=C1\CCCN1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
INMT O95050 3/20 0.44
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
MEN1 O00255 5/20 0.39
MAPT P10636 5/20 0.39
KMT2A Q03164 5/20 0.39
GAA P10253 4/20 0.39
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 3/20 0.39
PSMD14 O00487 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
IDE P14735 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18576755 0.93 INMT (0.38) INMTBRD4BRD2MEN1MAPT
SCHEMBL19243853 0.73
SCHEMBL11280612 0.73
SCHEMBL12425172 0.71
SCHEMBL13522211 0.71
SCHEMBL23937863 0.71
SCHEMBL13848641 0.71 BRD4 (0.43) INMTBRD4BRD2MEN1MAPT
SCHEMBL19481284 0.70 INMT (0.38) INMTBRD4BRD2
SCHEMBL26937821 0.70
SCHEMBL14191803 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433626-B2 Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-06 US disclosed
US-9211287-B2 Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-12-15 US disclosed
US-20150335654-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2015-11-26 US disclosed
US-20150258075-A1 PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-09-17 US disclosed
US-9034865-B2 Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-9035056-B2 Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-8921502-B2 Modified polymer compositions STYRON EUROPE GMBH (CH) 2014-12-30 US disclosed
US-8921502-B2 Modified polymer compositions STYRON EUROPE GMBH (CH) 2014-12-30 US disclosed
US-20140206711-A1 PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2014-07-24 US disclosed
EP-2516478-B1 MODIFIED POLYMER COMPOSITIONS STYRON EUROPE GMBH (CH) 2014-06-11 EP disclosed
US-20130217675-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-22 US disclosed
US-20130202830-A1 MODIFIED POLYMER COMPOSITIONS TRINSEO EUROPE GMBH (CH) 2013-08-08 US disclosed
US-20130202830-A1 MODIFIED POLYMER COMPOSITIONS TRINSEO EUROPE GMBH (CH) 2013-08-08 US disclosed
US-20130172320-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-07-04 US disclosed
WO-2011076377-A1 MODIFIED POLYMER COMPOSITIONS STYRON EUROPE GMBH (CH) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150258075-A1 PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE HTR1B, HTR2B, HTR2A INMT 107/4885BRD4 2075/4885BRD2 1284/4885
US-20130172320-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR3B, HTR4, HTR2C INMT 44/4885BRD4 575/4885BRD2 890/4885
US-20140206711-A1 PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE HTR1B, HTR2B, HTR2A INMT 107/4885BRD4 2075/4885BRD2 1284/4885
US-20130217675-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR3B, HTR4, HTR2C INMT 44/4885BRD4 575/4885BRD2 890/4885
US-20150335654-A1 PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR3B, HTR4, HTR2C INMT 44/4885BRD4 575/4885BRD2 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.